BlackRock Inc. raised its stake in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 1.8% during the 4th quarter, HoldingsChannel reports. The fund owned 6,902,230 shares of the specialty pharmaceutical company’s stock after purchasing an additional 120,394 shares during the period. BlackRock Inc. owned about 0.13% of Supernus Pharmaceuticals worth $275,054,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Public Employees Retirement Association of Colorado bought a new stake in Supernus Pharmaceuticals during the 4th quarter valued at $188,000. Sigma Planning Corp bought a new stake in Supernus Pharmaceuticals during the 4th quarter valued at $219,000. Parametrica Management Ltd bought a new stake in Supernus Pharmaceuticals during the 4th quarter valued at $247,000. Quantbot Technologies LP acquired a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter worth $248,000. Finally, Intrust Bank NA boosted its position in shares of Supernus Pharmaceuticals by 37.6% in the 3rd quarter. Intrust Bank NA now owns 6,957 shares of the specialty pharmaceutical company’s stock worth $278,000 after purchasing an additional 1,901 shares in the last quarter. 95.63% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have recently weighed in on SUPN shares. B. Riley reissued a “buy” rating and issued a $50.00 price objective on shares of Supernus Pharmaceuticals in a research report on Monday, November 20th. ValuEngine cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Janney Montgomery Scott raised Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 price objective for the company in a research report on Monday, December 4th. Zacks Investment Research raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Wednesday, January 10th. Finally, BidaskClub raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 11th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Supernus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $51.36.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.02. The company had revenue of $80.40 million during the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a return on equity of 28.07% and a net margin of 18.95%. The business’s revenue for the quarter was up 41.5% compared to the same quarter last year. research analysts anticipate that Supernus Pharmaceuticals Inc will post 1.87 earnings per share for the current year.
In related news, VP Victor Vaughn sold 55,000 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $40.11, for a total value of $2,206,050.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 20,000 shares of the firm’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $48.04, for a total value of $960,800.00. Following the completion of the transaction, the vice president now owns 32,500 shares of the company’s stock, valued at approximately $1,561,300. The disclosure for this sale can be found here. Insiders sold a total of 165,750 shares of company stock valued at $7,133,973 in the last 90 days. 6.70% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://sportsperspectives.com/2018/03/12/blackrock-inc-buys-120394-shares-of-supernus-pharmaceuticals-inc-supn.html.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.